Workflow-First Vertical AI in Biopharma

This carveout is what lets AI enter biopharma before it has to replace the compliance stack. Early drafting is usually where teams assemble source documents, fill templates, and circulate redlines before any formal approval. That work matters, but it is not yet the signed, locked record that GMP and Part 11 systems are built to control. So a product like Raycaster can speed up authoring while Veeva and IQVIA remain the place where the final regulated artifact is reviewed, signed, archived, and inspected.

• In practice, this means the AI sits in the messy middle of the workflow. Teams upload an RFI, Module 3 template, or due diligence packet, get a prefilled draft with citations, edit it, then move the finished version into a validated system of record for formal approval and submission.
  1 sacra 2 sacra
• That is the same boundary other life sciences software has used to expand. Benchling won early by digitizing research notebooks and workflows before selling validated cloud features for GxP use, while Veeva built its moat around submission content, approvals, archives, and auditable process control.
  4 veeva 5 sacra 6 sacra
• The commercial implication is that complementary vendors can land faster than replacement vendors. Buying an authoring layer is a smaller organizational bet than ripping out Veeva or IQVIA, because the compliant memory of the company stays in place and the new tool only accelerates draft generation and review prep.
  1 sacra 3 fda 4 veeva

Over time, the winning AI vendors in life sciences will move step by step toward the signature boundary. The near term path is to dominate pre submission drafting, capture edits and approval logic, and then push deeper into validated review flows. The company that owns that handoff cleanly will be best positioned to turn workflow assistance into system of record power.